pubrio
Lifordi Immunotherapeutics, Inc.

Lifordi Immunotherapeutics, Inc.

United States · Research

Research

Lifordi is among the first companies to leverage the success of antibody-drug conjugates (ADC) in oncology to develop treatments for autoimmune and inflammatory disorders. We have demonstrated superior efficacy in multiple preclinical diseases models by targeting myeloid and lymphoid cells using a highly internalized cell surface membrane protein. As experienced drug developers with expertise in immunology and inflammatory diseases, a strong partnering track record, and funding from ARCH Venture Partners, 5AM Ventures, and Atlas Venture to support initial clinical data, we can change how immune and inflammatory diseases are treated.

Company Insights
Company Overview

2023

Founded

Research

Industry

United States

Location

103,252,878

Ranking

22 employees

Size

Similar Companies

Get full access to view complete information

Frequently Asked Questions Regarding Lifordi Immunotherapeutics, Inc.

Start your journey today

Start with the platform — or start with a conversation

Use Pubrio on your own, or let our team help you with research, lead generation, or data integration.

pubrio

Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.​